专利检索_ .产生3'磷酸单酯的核糖核酸内切酶专利检索_ .产生3'磷酸单酯的核糖核酸内切酶专利检索查询

子分类：

序号	专利名	申请号	申请日	公开（公告）号	公开（公告）日	发明人
121	Use of angiogenin or angiogenin agonists for treating diseases and disorders	US14810983	2015-07-28	US09789168B2	2017-10-17	Matthew McDonagh; Benjamin Cocks; Angus Tester; Peter Hobman; Andrew Brown; Michelle Rowney
The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.
122	CONSTRUCT FOR THE DELIVERY OF A MOLECULE INTO THE CYTOPLASM OF A CELL	US15509018	2015-09-07	US20170260274A1	2017-09-14	Michaela Arndt; Jürgen Krauss; Stefan Kiesgen
Described is a construct comprising (a) a targeting moiety; (b) a fusogenic moiety consisting one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence DRGWGNGCGLFGKGGI (SEQ ID NO:1) or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1; and (c) a molecule which is to be delivered into the cytoplasm of a cell. Moreover, described is a pharmaceutical composition comprising the construct according to the invention and optionally a pharmaceutical acceptable carrier. Further, described is a kit comprising one or more fusogenic sequence(s) derived from dengue virus glycoprotein E comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 8 substitutions, deletions, or insertions in comparison to SEQ ID NO:1. Further, described is the use of one or more fusogenic sequence(s) derived from dengue virus glycoprotein E for use in delivery of a therapeutic moiety, a detectable moiety, a nucleic acid molecule, preferably an siRNA, a carrier molecule, preferably a nanoparticle, a liposome and a viral vector into the cytoplasm of a cell.
123	Viral Conjunctivitis Treatment Using Ranpirnase and/or Amphinase	US15604523	2017-05-24	US20170258876A1	2017-09-14	Brian Strem
The present specification discloses Ranpirnase and Amphinase, compositions comprising Ranpirnase and/or Amphinase, and methods and uses to treat a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduce or suppress a level of virus or viral titer, reduce or suppress viral replication, reduce or suppress protein synthesis, reduce or suppress a level of a tRNA, reduce or suppress a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, promote the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reduce or suppress a NFκB pathway signal using Ranpirnase, Amphinase or compositions comprising Ranpirnase and/or Amphinase.
124	NOVEL FERMENTED MILK PRODUCT AND METHOD FOR PRODUCING THE SAME	US15450596	2017-03-06	US20170173082A1	2017-06-22	Aiko OHMACHI; Hiroaki MATSUYAMA; Yoshikazu MORITA; Yuko ISHIDA; Takayuki NARA; Ken KATO; Atsushi SERIZAWA; Hiroshi UENO; Hiroshi URAZONO
The invention relates to provide a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.
125	METHODS OF TREATING ZIKA VIRUS, MERS-COV, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITUS, AND RHINOVIRUS IN MAMMALIAN PATIENTS	US15429046	2017-02-09	US20170157219A1	2017-06-08	Thomas W. Hodge, III
Viral infections in mammals can be treated and prophylactically prevented by systemic administration of ranpirnase and three other ribonucleases that are highly homologous with it and that have activities that are highly similar to it. Experimental results against Zika virus, Middle East Respiratory Syndrome Coronavirus (“MERS-CoV”), Chikungunya virus, Venezuelan equine encephalitis, and rhinovirus-14 are disclosed.
126	METHODS AND COMPOSITIONS FOR MODULATING IMMUNE TOLERANCE	US15404189	2017-01-11	US20170119858A1	2017-05-04	Arya Biragyn; Kouji Matsushima; Dolgor Baatar
The instant invention provides methods and compositions for modulation of the immune system. Specifically, the present disclosure provides methods and compositions for increasing T cell mediated immune response useful in the treatment of cancer and chronic infection.
127	Methods for control of flux in metabolic pathways	US13132721	2009-12-14	US09637746B2	2017-05-02	Daniel Klein-Marcuschamer
The invention pertains to a method for preparing cells that can be used as biocatalysts by inducing in them a growth-decoupled state, in which interferase inhibits the expression of genes except the ones that code for the pathway enzymes of interest. mRNAs that code for interferase-resistant products are overexpressed in the background of a metabolically-frozen cell. Enzymes that compete for a substrate or product of the pathway of interest may be altered such that the enzyme is sensitive to a site-specific protease, which protease is inducible in the host cell.
128	Fermented milk product and method for producing the same	US14418285	2012-07-31	US09629878B2	2017-04-25	Aiko Ohmachi; Hiroaki Matsuyama; Yoshikazu Morita; Yuko Ishida; Takayuki Nara; Ken Kato; Atsushi Serizawa; Hiroshi Ueno; Hiroshi Urazono
The invention relates to provide a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and lactoperoxidase and/or lactoperoxidase hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.3 to 23.
129	Viral Conjunctivitis Treatment Using Ranpirnase And/Or Amphinase	US15275442	2016-09-25	US20170087223A1	2017-03-30	Brian Strem
The present specification discloses Ranpirnase and Amphinase, compositions comprising Ranpirnase and/or Amphinase, and methods and uses to treat a viral conjunctivitis, an epidemic keratoconjunctivitis, and/or a pharyngoconjunctival fever, reduce or suppress a level of virus or viral titer, reduce or suppress viral replication, reduce or suppress protein synthesis, reduce or suppress a level of a tRNA, reduce or suppress a level of an inflammation inducing molecule and/or an inflammation inducing prostaglandin, stimulate or enhance a peroxisome proliferator-activated receptor (PPAR) pathway signal, promote the resolving phenotypic change of M1 to M2, modulate Th1 and Th2 cytokines, and/or reduce or suppress a NFκB pathway signal using Ranpirnase, Amphinase or compositions comprising Ranpirnase and/or Amphinase.
130	METHODS AND PHARMACEUTICALS FOR TREATMENT OF VIRAL INFECTIONS OF THE EYE	US15180270	2016-06-13	US20160361392A1	2016-12-15	Luis SQUIQUERA; Jamie Sulley
Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.
131	ACTIN BINDING PEPTIDES AND COMPOSITIONS COMPRISING SAME FOR INHIBITING ANGIOGENESIS AND TREATING MEDICAL CONDITIONS ASSOCIATED WITH SAME	US15113187	2015-01-29	US20160340659A1	2016-11-24	Oded SHOSEYOV; Betty SCHWARTZ; Shani DORON; Liron NESIEL; Assaf FRIEDLER; Hadar AMARTELY; Levava ROIZ; Patricia SMIRNOFF; Iris LEWIN
The present invention, in some embodiments thereof, relates to biologically active peptides and, more particularly, but not exclusively, to peptides from T2 RNase (RNASET2) having actin binding, pharmaceutical compositions comprising the same, therapeutic use thereof and methods for their production.
132	Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity	US14017885	2013-09-04	US09481878B2	2016-11-01	Chien-Hsing Chang; David M. Goldenberg; Edmund A. Rossi
The present invention concerns methods and compositions for forming immunotoxin complexes having a high efficacy and low systemic toxicity. In preferred embodiments, the toxin moiety is a ranpirnase (Rap), such as Rap(Q). In more preferred embodiments, the immunotoxin is made using dock-and-lock (DNL) technology. The immunotoxin exhibits improved pharmacokinetics, with a longer serum half-life and significantly greater efficacy compared to toxin alone, antibody alone, unconjugated toxin plus antibody or even other types of toxin-antibody constructs. In a most preferred embodiment the construct comprises an anti-Trop-2 antibody conjugated to Rap, although other combinations of antibodies, antibody fragments and toxins may be used to form the subject immunotoxins. The immunotoxins are of use to treat a variety of diseases, such as cancer, autoimmune disease or immune dysfunction.
133	Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy	US13901737	2013-05-24	US09446123B2	2016-09-20	Edmund A. Rossi; Chien-Hsing Chang; David M. Goldenberg
The present invention concerns multimeric complexes based on antibody fusion proteins comprising an AD moiety attached to the C-terminal end of each antibody light chain. The complexes further comprise effector moities attached to DDD moieties. Two copies of the DDD moiety form a dimer that binds to the AD moiety. The complexes may be trimers, pentamers, hexamers or other multimers. The effector moieties may be selected from a second antibody or antigen-binding fragment thereof, a cytokine, an interferon, a toxin, an antigen, a xenoantigen, a hapten, a protamine, a hormone, an enzyme, a ligand-binding protein, a pro-apoptotic agent and an anti-angiogenic agent. Surprisingly, attachment of the AD moiety to the C-terminal end of the antibody light chain results in improved pharmacokinetics and in vivo stability and efficacy, compared to homologous complexes wherein the AD moiety is attached to the antibody heavy chain.
134	POLLEN PREFERRED PROMOTERS AND METHODS OF USE	US14611399	2015-02-02	US20160251669A1	2016-09-01	Andrew Mark Cigan; Shai Joshua Lawit
Compositions and methods for regulating expression of heterologous nucleotide sequences in a plant are provided. Compositions include nucleotide sequences encompasses a strong pollen preferred promoter which drives strong, specific expression of gene products in pollen. Also provided is a method for expressing a heterologous nucleotide sequence in a plant using a promoter sequence disclosed herein.
135	Method of treating eosinophilia by administering an immunomodulating peptide	US14022795	2013-09-10	US09315544B2	2016-04-19	Margaret Dah-Tsyr Chang; Lin-Shien Fu; Shun-Lung Fang
A method of treating or preventing inflammatory related diseases in a subject in need thereof comprising administering to said subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is provided. A method for inhibiting cancer metastasis or growth of tumor in a subject in need thereof, comprising administering to the subject a pharmaceutically effective amount of a composition comprising an immune modulating polypeptide of SEQ ID NO: 1 is also provided.
136	NOVEL POWDERED MILK PRODUCT AND METHOD FOR PRODUCING THE SAME	US14417888	2012-07-31	US20160015790A1	2016-01-21	Aiko OHMACHI; Hiroaki MATSUYAMA; Yoshikazu MORITA; Yuko ISHIDA; Takayuki NARA; Ken KATO; Atsushi SERIZAWA; Hiroshi UENO; Hiroshi URAZONO
The invention relates to a powdered milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 1.4 to 24 mg/15 g, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.03 to 1.3.
137	NOVEL PROTEIN MATERIAL	US14418210	2012-07-31	US20150297690A1	2015-10-22	Aiko OHMACHI; Hiroaki MATSUYAMA; Yoshikazu MORITA; Yuko ISHIDA; Takayuki NARA; Ken KATO; Atsushi SERIZAWA
The invention relates to a protein material includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and lactoperoxidase and/or lactoperoxidase hydrolysate, in the mass ratio to angiogenin and/or angiogenin hydrolysate of 0.3 to 20.
138	Use of angiogenin or angiogenin agonists for treating diseases and disorders	US12992501	2009-05-14	US09119818B2	2015-09-01	Matthew McDonagh; Benjamin Cocks; Angus Tester; Peter Hobman
The invention provides a method of treating a disorder characterized by elevated or dysregulated myostatin, disorders where the interaction between follistatin and angiogenin can be used to improve function in tissues, neurological diseases or disorders, spinal injuries or diseases, bone diseases or disorders, diseases involving glucose homeostasis, wound healing, neuroprotection, nervous system functional support or managing metabolic diseases, the method comprising administering an effective amount of angiogenin or an angiogenin agonist. Compositions and neutraceuticals comprising angiogenin are also provided.
139	NOVEL CHEESE AND METHOD FOR PRODUCING THE SAME	US14418242	2012-07-31	US20150230486A1	2015-08-20	Aiko Ohmachi; Hiroaki Matsuyama; Yoshikazu Morita; Yuko Ishida; Takayuki Nara; Ken Kato; Atsushi Serizawa; Hiroshi Ueno; Hiroshi Urazono
The invention relates to a cheese includes angiogenin and/or angiogenin hydrolysate in an amount of 6.5 mg/100 g to 160 mg/100 g, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.02 to 1.6.
140	NOVEL FERMENTED MILK PRODUCT AND METHOD FOR PRODUCING THE SAME	US14418298	2012-07-31	US20150230485A1	2015-08-20	Aiko Ohmachi; Hiroaki Matsuyama; Yoshikazu Morita; Yuko Ishida; Takayuki Nara; Ken Kato; Atsushi Serizawa; Hiroshi Ueno; Hiroshi Urazono
The invention relates to a fermented milk product includes angiogenin and/or angiogenin hydrolysate in an amount of 0.9 mg/100 g to 150 mg/100 g, and cystatin and/or cystatin hydrolysate in the mass ratio to the angiogenin and/or angiogenin hydrolysate of 0.006 to 1.7.

2 3 4 5 6 7 8 9 10 11

该功能需要专业版企业版VIP权限，您可以：